You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FLT3-mutated AML

Showing 1 - 25 of 2,377
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)

Available
  • FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
  • (no location specified)
Oct 18, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

Suspended
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib 40 MG Oral Tablet
  • +4 more
  • Lexington, Kentucky
    University of Kentucky
Oct 27, 2022

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022

Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Chengdu, Sichuan, China
    West China hospital of Sichuan University
Nov 1, 2021

Acute Myeloid Leukemia Trial in Worldwide (Midostaurin, Placebo)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Hong Kong, Hong Kong
  • +40 more
Jan 20, 2023

Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)

Approved for marketing
  • Acute Myeloid Leukemia (AML)
  • FMS-like Tyrosine Kinase-3 (FLT3) Mutations
  • Los Angeles, California
  • +38 more
Apr 18, 2021

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)

Recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Boston, Massachusetts
  • +2 more
Jan 18, 2023

Acute Myeloid Leukemia Trial in United States (Gilteritinib, Midostaurin, Daunorubicin)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Scottsdale, Arizona
  • +43 more
Nov 17, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)

Not yet recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • (no location specified)
May 24, 2023

Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)

Recruiting
  • Acute Myeloid Leukemia
  • Miami, Florida
    Miami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022

AML, Adult Trial in Berne (HDM201, Midostaurin)

Terminated
  • AML, Adult
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
Oct 3, 2022

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

Acute Myeloid Leukemia Trial in Germany (Sunitinib)

Completed
  • Acute Myeloid Leukemia
  • Hamburg, Germany
  • +4 more
Feb 22, 2020

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Xospata in Relapsed or Refractory Acute Myeloid Leukemia With

Recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Gilteritinib Exposure
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +4 more
Aug 18, 2022

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations Trial in Worldwide (Crenolanib, Cytarabine,

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
  • Sacramento, California
  • +61 more
Apr 28, 2021

Acute Myeloid Leukemia Trial in Canada, United States (Midostaurin, Standard of Care)

Completed
Has Results
  • Acute Myeloid Leukemia
  • La Jolla, California
  • +18 more
Mar 12, 2021

Acute Myeloid Leukemia Trial in Germany (midostaurin (PKC412))

Completed
  • Acute Myeloid Leukemia
  • midostaurin (PKC412)
  • Chemnitz, Germany
  • +9 more
Aug 5, 2020

Patterns and Key Healthcare Resource Use in Acute Myeloid

Completed
  • Acute Myeloid Leukemia (AML)
  • Treatment patterns among AML patients
  • AML-related healthcare resources
  • Charlotte, North Carolina
    Sermo
Jan 25, 2022

Acute Myeloid Leukemia Trial (Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy)

Withdrawn
  • Acute Myeloid Leukemia
  • (no location specified)
May 18, 2022